올리고뉴클레오티드 치료제 시장 규모, 점유율 및 성장 분석 : 유형별, 작용기서별, 전달 기술별, 투여 경로별, 용도별, 표적 분자별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Oligonucleotide Therapeutics Market size was valued at USD 4.7 Billion in 2024 and is poised to grow from USD 5.57 Billion in 2025 to USD 21.66 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The oligonucleotide therapeutics market is driven by the integration of advanced genetic insights with innovative chemical engineering, allowing for precise modulation of gene expression. This sector includes targeted therapies like antisense oligonucleotides and siRNA, which are reshaping treatment for both rare genetic disorders and chronic illnesses through high specificity and expedited design processes. While earlier challenges in stability and delivery hindered progress, recent breakthroughs have facilitated significant advancements, evidenced by successful therapies like nusinersen and patisiran that validated the approach. AI is now enhancing innovation by streamlining target discovery, sequence design, and manufacturing efficiency, making it essential for both startups and established firms to navigate this complex landscape effectively. This convergence of technology and biology is unlocking new opportunities across various therapeutic areas.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oligonucleotide Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oligonucleotide Therapeutics Market Segments Analysis

Global oligonucleotide therapeutics market is segmented by type, mechanism of action, delivery technology, route of administration, application, target molecule, end user and region. Based on type, the market is segmented into Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Aptamers, MicroRNA (miRNA) Therapeutics, CpG Oligonucleotides, Phosphorodiamidate Morpholino Oligonucleotides (PMOs) and Other Oligonucleotide Therapeutics. Based on mechanism of action, the market is segmented into Gene Silencing, Splice Modulation, Translational Arrest, Immune Stimulation, RNA Degradation and Target Binding/Inhibition. Based on delivery technology, the market is segmented into Lipid Nanoparticle (LNP)-Based Delivery, GalNAc-Conjugated Delivery, Polymer-Based Delivery, Peptide-Conjugated Delivery, Antibody-Oligonucleotide Conjugates and Other Delivery Platforms. Based on route of administration, the market is segmented into Subcutaneous, Intravenous, Intrathecal, Intramuscular and Other Routes of Administration. Based on application, the market is segmented into Neurological Disorders, Rare Genetic Disorders, Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Renal Disorders, Ophthalmic Disorders and Other Therapeutic Applications. Based on target molecule, the market is segmented into RNA-Targeting Therapeutics and DNA-Targeting Therapeutics. Based on end user, the market is segmented into Hospitals & Specialty Clinics, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oligonucleotide Therapeutics Market

A key market driver for the global oligonucleotide therapeutics market is the increasing prevalence of genetic disorders and chronic diseases that require innovative treatment solutions. As the understanding of genetic conditions expands, there is a growing demand for targeted therapies that can modify gene expression and address the underlying causes of diseases. Advances in oligonucleotide synthesis technologies and delivery mechanisms further enhance the efficacy and specificity of therapies, bolstering their clinical adoption. Furthermore, the expanding pipeline of oligonucleotide-based treatments reinforces investor confidence and encourages research and development activities, fostering a conducive environment for market growth.

Restraints in the Global Oligonucleotide Therapeutics Market

One significant market restraint for the global oligonucleotide therapeutics market is the high costs associated with research, development, and manufacturing processes. The intricate and specialized nature of oligonucleotide synthesis, coupled with stringent regulatory demands, results in substantial financial burdens for companies. This economic barrier can deter smaller biotech firms from entering the market and may limit investment in innovative treatments. Additionally, the requirement for extensive clinical trials to ensure safety and efficacy further escalates costs. As a result, many potential therapies may remain uncommercialized, hindering overall market growth and accessibility to patients in need.

Market Trends of the Global Oligonucleotide Therapeutics Market

The Global Oligonucleotide Therapeutics market is witnessing a notable trend towards enhanced targeted delivery platforms that enable the more precise administration of oligonucleotide drugs to specific tissues and cell types. This advancement not only increases the therapeutic index but also minimizes systemic exposure, thus improving patient outcomes. Innovations in conjugates, lipid-based carriers, and novel peptide or antibody-linker systems are driving the development of platform approaches, fostering robust collaborations between biotech firms and delivery specialists. This synergy not only broadens the spectrum of treatable indications but also bolsters confidence in the potential of oligonucleotide therapies to tackle previously hard-to-reach disease mechanisms with heightened safety and efficacy.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oligonucleotide Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Antisense Oligonucleotides (ASOs)
• Small Interfering RNA (siRNA)
• Aptamers
• MicroRNA (miRNA) Therapeutics
• CpG Oligonucleotides
• Phosphorodiamidate Morpholino Oligonucleotides (PMOs)
• Other Oligonucleotide Therapeutics

Global Oligonucleotide Therapeutics Market Size by Mechanism of Action & CAGR (2026-2033)

• Market Overview
• Gene Silencing
• Splice Modulation
• Translational Arrest
• Immune Stimulation
• RNA Degradation
• Target Binding/Inhibition

Global Oligonucleotide Therapeutics Market Size by Delivery Technology & CAGR (2026-2033)

• Market Overview
• Lipid Nanoparticle (LNP)-Based Delivery
• GalNAc-Conjugated Delivery
• Polymer-Based Delivery
• Peptide-Conjugated Delivery
• Antibody-Oligonucleotide Conjugates
• Other Delivery Platforms

Global Oligonucleotide Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Subcutaneous
• Intravenous
• Intrathecal
• Intramuscular
• Other Routes of Administration

Global Oligonucleotide Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Neurological Disorders
• Rare Genetic Disorders
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Renal Disorders
• Ophthalmic Disorders
• Other Therapeutic Applications

Global Oligonucleotide Therapeutics Market Size by Target Molecule & CAGR (2026-2033)

• Market Overview
• RNA-Targeting Therapeutics
• DNA-Targeting Therapeutics

Global Oligonucleotide Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Global Oligonucleotide Therapeutics Market Size & CAGR (2026-2033)

• North America (Type, Mechanism of Action, Delivery Technology, Route of Administration, Application, Target Molecule, End User)
  • US
  • Canada
• Europe (Type, Mechanism of Action, Delivery Technology, Route of Administration, Application, Target Molecule, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Mechanism of Action, Delivery Technology, Route of Administration, Application, Target Molecule, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Mechanism of Action, Delivery Technology, Route of Administration, Application, Target Molecule, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Mechanism of Action, Delivery Technology, Route of Administration, Application, Target Molecule, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Ionis Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wave Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avidity Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silence Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProQR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dyne Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PepGen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stoke Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SpliSense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NOXXON Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anjarium Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ribo Life Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sterna Biologicals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations